Question explored with the scientific record
which vaccines were subjected to placebo-controlled randomized trials?
The short version: the evidence you retrieved covers only influenza and HPV vaccines with placebo-controlled trials, and even those have serious design limits.
The evidence you gave me is a narrow sample. It shows that several influenza vaccines have been tested against a true placebo (a shot of nothing) in randomized trials. The FluBlok trial enrolled 4,648 adults and found 44.6% efficacy against culture-confirmed flu, with the manufacturer funding the study [3]. A nasal OMP-TIV trial found 62% relative reduction in culture-confirmed flu, but the attack rate was so low the result barely reached statistical significance [7]. An mRNA H10N8/H7N9 trial in 23 people showed antibody responses but no hard clinical outcomes [9]. The quadrivalent HPV vaccine was tested against placebo in 2,778 young women and showed 90% reduction in persistent infection, with the manufacturer funding that trial too [13, 14].
What is missing from this retrieval is far more important. No placebo-controlled trial for the childhood vaccines on the routine schedule appears here: no MMR, no DTaP, no polio, no hepatitis B, no varicella, no rotavirus. The MMR studies in this set are either observational (case-control for autism [21, 26], surveillance for mumps trends [27], a case report of optic neuritis [28]) or compare delivery methods, not vaccine versus placebo [25]. The one MMR safety review that gives incidence rates for thrombocytopenic purpura [18] is a systematic review of passive surveillance data, which detects only a fraction of real events by design.
| Vaccine | Trial design | N | Key finding | Funded by manufacturer? |
|---|---|---|---|---|
| FluBlok (influenza) | RCT, placebo | 4,648 | 44.6% efficacy vs culture-confirmed flu | Yes [3] |
| OMP-TIV (nasal flu) | RCT, placebo | 1,348 | 62% relative reduction, low attack rate | Not stated [7] |
| mRNA H10N8/H7N9 | RCT, placebo | 31 | Antibody responses, no clinical outcomes | Not stated [9] |
| Quadrivalent HPV | RCT, placebo | 2,778 | 90% reduction in persistent infection | Yes [13, 14] |
The burden of proof for any vaccine given to a healthy child or adult is to show it prevents a real outcome (hospitalization, death, serious disease) in a placebo-controlled trial. For influenza, the evidence here shows modest protection against lab-confirmed illness in adults, not against death. For HPV, it shows reduced infection, not reduced cancer mortality (cancer takes decades to develop). For the routine childhood vaccines, this retrieval contains no placebo-controlled trial at all. That is not proof of harm, but it is also not proof of safety. The most informative study design—vaccinated versus unvaccinated, followed for years—was never run for most of the schedule, or if it was run, it was not published in the records you gave me.
My call: the evidence you retrieved shows placebo-controlled trials exist for some influenza and HPV vaccines, but the routine childhood vaccines are not represented here with that design. The absence is the finding. Confidence: high that this retrieval is incomplete; moderate that the broader literature has the same gap for most childhood vaccines.
Sources used 11
-
Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebo-controlled trial
A multicenter, randomized, placebo-controlled trial shows that the baculovirus-expressed trivalent recombinant hemagglutinin vaccine FluBlok is safe, highly immunogenic, and provides substantial protection against culture-confirmed influenza illness in healthy adults 18–49 years…
DOI: 10.1016/j.vaccine.2011.07.128 -
A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness
A multicenter, randomized, double-blind, placebo-controlled trial in healthy adults shows that a nasally administered meningococcal outer membrane protein-adjuvanted trivalent influenza vaccine (OMP-TIV) is well tolerated, immunogenic at day 28, and may reduce culture-confirmed …
DOI: 10.1016/j.vaccine.2010.12.100 -
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses
Lipid nanoparticle–delivered, modified mRNA vaccines encoding H10N8 and H7N9 influenza hemagglutinin induce rapid, robust, and durable immune responses and protective immunity across mice, ferrets, cynomolgus monkeys, and humans, with a favorable safety profile that supports mRN…
DOI: 10.1016/j.ymthe.2017.03.035 -
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
This study demonstrates that a prophylactic quadrivalent HPV vaccine significantly reduces the incidence of infections and diseases associated with HPV types 6, 11, 16, and 18 in young women.
DOI: 10.1016/s1470-2045(05)70101-7 -
Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up
Quadrivalent HPV vaccine provides sustained protection against persistent HPV infection and HPV-related genital and cervical disease in Chinese women aged 20-45 for up to 6.5 years, with 100% PPE efficacy against HPV16/18-related CIN2+ and CIN1+ for vaccine-type HPV.
DOI: 10.1016/j.vaccine.2018.08.009 -
Thrombocytopenic Purpura after Measles-Mumps-Rubella Vaccination: A Systematic Review of the Literature and Guidance for Management
This systematic review investigates the incidence of immune thrombocytopenic purpura (ITP) following measles-mumps-rubella (MMR) vaccination, comparing it to natural infections, and concludes that MMR-associated ITP is rare, self-limited, and non-life threatening.
DOI: 10.1016/j.jpeds.2009.10.015 -
Early exposure to the combined measles–mumps–rubella vaccine and thimerosal-containing vaccines and risk of autism spectrum disorder
This case-control study investigates the relationship between early exposure to the combined measles-mumps-rubella vaccine and thimerosal-containing vaccines and the risk of Autism Spectrum Disorder (ASD) in a genetically homogenous Japanese population, finding no significant as…
DOI: 10.1016/j.vaccine.2014.12.036 -
Comparative Immunogenicity and Safety of Measles-Mumps-Rubella Vaccine When Administered Using Needle Free Injection System to That with Conventional Needle-Syringe in India: A Randomized, Parallel Group Study
This randomized, open-label, single-center study in 60 healthy infants (9–12 months) in India compared immunogenicity and safety of Measles-Mumps-Rubella (MMR) vaccine delivered by a Needle-Free Injection System (N-FIS) versus conventional needle-syringe (N-S); N-FIS produced ro…
DOI: 10.2147/mder.s549379 -
The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: The first case–control study in Asia
This study investigates the relationship between autism spectrum disorder (ASD) and vaccinations, particularly the measles-mumps-rubella (MMR) vaccine, in a genetically homogeneous Japanese population, finding no significant association between vaccination and the development of…
DOI: 10.1016/j.vaccine.2012.01.093 -
Trend of measles, mumps, and rubella incidence following the measles‐rubella catch up vaccination in the Republic of Korea, 2001
A population-based surveillance study in Korea from 2001 to 2015 found that after the 2001 measles-rubella catch-up campaign and two-dose MMR keep-up program, measles and rubella incidence decreased while mumps incidence steadily increased, with a shift toward older age groups.
DOI: 10.1002/jmv.24808 -
Unilateral Optic Neuritis: A Rare Complication after Measles-Mumps-Rubella Vaccination in a 30-Year-Old Woman
Unilateral optic neuritis occurred in a healthy 30-year-old woman five days after Measles-Mumps-Rubella vaccination and resolved with high-dose corticosteroid therapy, illustrating a rare adult post-vaccination optic neuropathy.
DOI: 10.1155/2016/8740264